CytRx gains on interim aldoxorubicin data

CytRx Corp. (NASDAQ:CYTR) jumped $0.71 (19%) to $4.41 on Monday after the company presented data from two Phase Ib trials of combinations including its aldoxorubicin to treat sarcomas and solid tumors.

An interim analysis of a Phase Ib study testing aldoxorubicin plus ifosfamide and mesna as first-line therapy for patients with locally advanced, unresectable and/or metastatic sarcomas showed that one out of seven evaluable patients had a complete response after five treatment cycles. ...